Component

Human serum total RA after deconjugation

Human serum total RA after deconjugation

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Extract providing 500 mg RA produced total serum Cmax of 162.20 nM fasting and 142.20 nM fed.

    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_model
    Healthy volunteers; six PK observations per condition, 11 participants across study arms.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
    plain_language
    Extract providing 500 mg RA produced total serum Cmax of 162.20 nM fasting and 142.20 nM fed.
    primary_references
    Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. | https://pubmed.ncbi.nlm.nih.gov/25978046/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC4433273/ | https://doi.org/10.1371/journal.pone.0126422
    source_locator
    Reviewed reference ra-human-total-exposure; Table 3: median total Tmax 1 h fasting, 3 h fed. Total includes hydrolysable conjugates; neither Tmax is a half-life.

    Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 35–41

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Healthy volunteers; six PK observations per condition, 11 participants across study arms. · Recorded from source · Recorded from source

    ### ra-human-total-exposure Extract providing 500 mg RA produced total serum Cmax of 162.20 nM fasting and 142.20 nM fed. Table 3: median total Tmax 1 h fasting, 3 h fed. Total includes hydrolysable conjugates; neither Tmax is a half-life. Model and exposure: Healthy volunteers; six PK observations per condition, 11 participants across study arms. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. | 2015 | https://pubmed.ncbi.nlm.nih.gov/25978046/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC4433273/ | https://doi.org/10.1371/journal.pone.0126422 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.